Ignite Creation Date:
2024-05-06 @ 10:20 AM
Last Modification Date:
2024-10-26 @ 12:28 PM
Study NCT ID:
NCT03232177
Status:
COMPLETED
Last Update Posted:
2021-07-21
First Post:
2017-07-11
Brief Title:
Anagre Cap in Patients With High-Risk Essential Thrombocythemia
Sponsor:
Yuhan Corporation
Organization:
Yuhan Corporation
Study Overview
Official Title:
A Multicenter Open-label Clinical Study for Efficacy and Safety Evaluation of Anagrelide in Patients With Treatment-naïve High-risk Essential Thrombocythemia as a Primary Treatment
Status:
COMPLETED
Status Verified Date:
2021-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is to evaluate the efficacy and safety according to incremental dosing for 8 weeks and duration of administration for 1 year in patients with high-risk essential thrombocythemia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None